Dynamic Infection Kinetics for Early Sepsis Diagnosis and Monitoring in Adult Oncology Patients
Official title: Dynamic Infection Kinetics as an Early Diagnostic and Monitoring Tool for Sepsis in Oncology Patients
Run by Sohag University · NCT07795502 · Data updated 2026-11-12
This study tests whether tracking changes in infection biomarkers and blood culture results over time can help detect sepsis earlier and track treatment response in adults with cancer.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years and up |
| Sex | All |
| Enrollment | 100 (estimated) |
| Sponsor | Sohag University Academic / other |
| Locations | 1 site (Sohag, Sohag Governorate) |
| Status | Recruiting |
| Started | July 15, 2026 |
| Main results expected | March 7, 2027 |
| Study ends | August 15, 2027 |
| Registry record updated | September 1, 2026 |
| Trial ID | NCT07795502 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults with current solid or hematologic cancer, with clinical suspicion of sepsis and at least one blood culture obtained.
✕Probably not a fit
Patients who do not develop sepsis or whose biomarker trajectories do not correlate with outcomes may not experience direct benefit.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This is a prospective observational cohort study conducted at Sohag Oncology Center. It will enroll adult patients with solid or hematologic cancers who have suspected sepsis and at least one blood culture collected as part of routine care. Researchers will collect clinical, laboratory, and microbiological data, including blood culture results, time to positivity, culture clearance, CRP, and procalcitonin levels, to examine dynamic infection kinetics. The goal is to see if serial biomarker and culture metrics improve early detection of sepsis and provide insight into disease severity and treatment response. Interventions are not part of the study; data are observed from standard clinical practice.
Why it matters
Potential benefit: If successful, clinicians may detect sepsis earlier and tailor treatment more effectively based on biomarker and culture dynamics.
How similar studies have gone: Previous research has shown that infection biomarkers and culture kinetics can reflect infection dynamics, but this exact dynamic, oncology-focused approach is less established.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Confirmed diagnosis of a solid or hematological malignancy. * Clinical suspicion of sepsis according to treating physicians. * At least one blood culture obtained before or shortly after initiation of antimicrobial therapy. * Availability for clinical follow-up during hospitalization. Exclusion Criteria: * Patients receive palliative care only. * Absence of blood culture sampling. * Incomplete clinical or laboratory data. * Refusal to participate in the study, when applicable.
Where it's running
-
Sohag Oncology Center
Sohag, Sohag Governorate, Egypt Recruiting
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
Ruta C and Vitamin C in Sepsis: Adding antioxidants to standard care
This trial tests whether adding Ruta C (rutin plus vitamin C) or vitamin C alone to standard sepsis treatment helps adults in the ICU stay shorter and recover better.
-
Early detection of sepsis-related blood clotting problems in severe burn patients
This study tests how well the JAAM-2 score can detect sepsis-induced coagulopathy early in adults with severe burns who develop sepsis in the ICU.
-
Neutrophil EMR3 as a biomarker for sepsis in ICU patients
Researchers will test whether measuring EMR3 on neutrophils helps diagnose sepsis, monitor progression, and predict outcomes in adults in Chinese ICUs.
-
Thymalfasin added to standard care for adults with sepsis and immune dysfunction
This study tests whether thymosin alpha-1 helps restore immune function in adults with sepsis who have weakened immunity.
-
Multicenter group study of sepsis and ARDS in China
This study tests how sepsis and ARDS differ among adults across several Chinese hospitals and builds a biobank to understand why some patients do better or worse.
-
Non-invasive hemodynamic guidance for sepsis care on medical wards
This trial tests whether guiding fluid and vasopressor therapy for sepsis using non-invasive hemodynamic measurements works better than standard care.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.